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Abstract
Misuse of organophosphate insecticides, even in case of domestic application, can be life threatening. We report
the case of siblings admitted with respiratory distress, pinpoint pupils and slurred speech. The symptoms appear
after spraying the skin by insecticides. Plasma pseudocholinesterase level appeared to be very low, consistent with
acute intoxication with organophosphate insecticide.
Management of organophosphate poisoning consists of airway management, administration of oxygen and fluid,
as well as atropine in increasing doses and pralidoxime. Decontamination of the patient’s skin and the removal of
the patient’s clothes are mandatory in order to avoid recontamination of the patient as well as the surrounding
healthcare personnel.
Plasma pseudocholinesterase analysis is a cheap and an easy indicator for organophosphate insecticides
intoxications and could be used for diagnosis and treatment monitoring.
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Introduction
Organophosphate insecticides are widely used in rural
areas. Intentional ingestion of organophosphates is asso-
ciated with a high mortality rate [1]. Organophosphate
intoxication (OI) induces irreversible inhibition of acet-
ylcholinesterase. Organophosphates phosphorylate the
serine hydroxyl group of acetylcholine, leading to accu-
mulation of acetylcholine at the cholinergic synapses [2].
This accumulation leads to weakness and fasciculation
of the muscle. In the central nervous system, neural
transmission is disrupted. If this blockade is not
reversed within 24 h, large amounts of acetylcholinester-
ase are permanently destroyed [3].
Acetylcholinesterase is found in red blood cells as well
as in nicotinic and muscarinic receptors. To determine
the severity and/or the elimination time of OI, one
should measure cholinesterase in blood, either by mea-
suring plasma pseudocholinesterase (PCE) or by measur-
ing the cholinesterase in erythrocytes (which is thought
to reflect the cholinesterase in neurons and neuromus-
cular junctions). The first method is widely available
and therefore commonly used [3,4].
Herein, we report a case of siblings who, upon being
sprayed with an organophosphate solution, developed
severe OI associated with central nervous system (CNS)
depression.
Case report
A 7-year-old previously healthy boy was brought into
the emergency department with vomiting and reduced
consciousness by his mother. He had been in good
health until he was found, 30 min prior to admission,
unresponsive in the bathroom. The mother was not able
to provide more information.
At admission, the health care personnel had smelled an
unspecified and unpleasant odour. The physical examina-
tion of the boy showed pinpoint pupils (2 mm diameter),
hypersalivation and lacrimation. He was responsive to
pain, but had slurred speech. His Glasgow Coma Scale
(GCS) score was 9. Upon presentation, his vital signs
included a rectal temperature of 36.8°C; heart rate, 117
beats/min; respiratory rate, 38 breaths/min; blood pres-
sure, 112/58 mmHg; and haemoglobin saturation, 96%.
Lung auscultation revealed bilateral wheezing. He had no
abdominal tenderness, distension or hepatomegaly. The
skin was warm and clammy with capillary refill (CR) of
less than 2 s. Eight minutes after admission, his heart
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respiratory arrest. After orotracheal intubation, mechani-
cal ventilation and atropine administration (0.02 mg/kg
every 5 min), the patient’s condition stabilized.
The cause of the symptoms was unclear, but intoxica-
tion with opiates or an organophosphorus compound
(OC) was considered [5]. The patient’ss y m p t o m s ,t h e
recovery after atropine administration and the occur-
rence of headache in the involved health care personnel
indicated probable OI.
Shortly thereafter, the boy’s 10-year-old sister, with the
exact same unpleasant odour, altered sensorium, vomit-
ing and respiratory distress, was brought to the emer-
gency department by the father. She was afebrile and had
a heart rate of 133 beats/min; the respiration was shallow
at a rate of 31 breaths/min with bilateral wheezing and
bronchial secretions. Her blood pressure was 131/76
mmHg, and the GCS was 15. Her pupils were 1 mm in
diameter, and the CR was prolonged up to 4 s. She was
stabilized with oxygen administration through a non-
rebreathing mask and a 20 ml/kg bolus of saline fluid
through a secured intravenous vascular catheter. Because
OI had been suspected earlier for her brother, atropine
(0.05 mg/kg) was given to prevent further decline.
Both children were transferred to the paediatric inten-
sive care unit (PICU).
All laboratory values were normal, except for a
decreased PCE. The boy’sP C Ew a s0 . 3k U / la n dt h e
girl’s 0.2 kU/l (laboratory reference range: 4.6-10.4 kU/l).
These clinical and biological findings confirmed our
diagnosis of OI.
Subsequently, the girl told us that they had been
spraying fluid from a bottle while playing in the bath-
room. Later on, the mother admitted that she had filled
the bottle with pesticide to eradicate insects in the
house, and subsequently analysis of the bottle’s solution
showed a high concentration of OC.
The boy was kept on mechanical ventilation for the
next 24 h. He was treated with large fluid infusions,
atropine (0.05 mg/kg every 15 min) and pralidoxime (25
mg/kg every 6 h).
The frequency of atropine administration was reduced
and finally stopped when symptoms such as bradycardia,
hypersecretion and bronchospams disappeared. Both
patients improved considerably, although the boy
showed fasciculations for an additional day. After the
atropine treatment had been stopped, pralidoxime was
slowly decreased and stopped after 6 days. His PCE level
was 4.3 kU/l on day 10 (Figure 1).
The sister was treated with two doses of atropine (0.05
mg/kg) and pralidoxime (25 mg/kg every 6 h). The pra-
lidoxime dosage was rapidly reduced and finally stopped
after 4 days. Her PCE level was 4.6 kU/l on day 10 as
well (Figure 1).
The children were discharged from the PICU on day 6
and from the hospital on day 10 without any sequelae.
Further evaluation of the siblings 2 weeks later showed
normal clinical findings, and the PCE values were within
the normal range.
Discussion
The striking similarity and timely fashion of the clinical
presentation of these siblings suggested either a toxic
environmental exposure or ingestion. Both children had
some elements of CNS depression, respiratory difficulty,
hypersecretion and miotic pupils. This constellation of
findings is highly suggestive of a cholinergic toxidrome,
and additional inquiry revealed exposure to OC.
OCs are commonly used in agricultural products,
including insecticides and defoliants. They are rapidly
absorbed by all routes of exposure, including dermal,
respiratory and gastrointestinal, and irreversibly inhibit
the enzyme acetylcholinesterase at cholinergic synapses,
resulting in excess cholinergic stimulation at the neuro-
muscular junction, the sympathetic and parasympathetic
nervous systems, and the CNS [3].
In our patients the absorption was probably via differ-
ent routes, the skin, and the mouth, and/or via the
respiratory tract while they were spraying the solution at
each other in the bathroom.
The initial management should be directed toward
securing and maintaining a stable patent airway and
assuring adequate gas exchange and end-organ perfu-
sion. Once these elements are stable and secure, efforts
can be directed toward establishing a definitive diagnosis
and treatment.
Unlike adults, infants mainly present with acute CNS
depression [6] and do not demonstrate the typical mus-
carinic effects. Symptoms such as fasciculation, brady-
cardia and acute respiratory failure are more common
in children [7].
Tachycardia, rather than bradycardia, has been noted
upon presentation in 49% of children presenting with
OI [6].
The acute respiratory failure in our cases was likely
multifactorial in origin, resulting from secretions and
bronchospasm from muscarinic stimulation. In addition,
stimulation of nicotinic receptors causes weakness and
paresis of the respiratory muscles [8].
The bradycardia event in our first case was most
probably secondary to an apneic episode.
Acute OI is a clinical diagnosis. Red blood cell choli-
n e s t e r a s el e v e l sa r eu s u a l l ym a r k e d l yd i m i n i s h e d ,b u t
this laboratory test is seldom readily available. Although
plasma PCE levels may be diminished as well, still there
is little correlation with acetylcholinesterase activity in
either the brain or at the neuromuscular junction [4,9].
However, the decrease in PCE levels may serve as a
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The diagnosis is therefore based on a history of expo-
sure, recognition of the cholinergic toxidrome, and
improvement or resolution of symptoms after appropri-
ate treatment [4,9,10].
Treatment is aimed at reversal of muscarinic signs
with atropine and enzyme reactivation by pralidoximes.
Frequent atropine doses or continuous titrated infusions
are used to achieve drying of secretions and the resolu-
tion of bradycardia [11,12]. Tachycardia, however, is not
a contraindication to atropine administration [12]. The
pupillary response (resolution of miosis) is not consid-
ered an end point of atropine therapy, as miosis may
persist for weeks after significant exposure [11]. In our
cases, the miosis was resolved within 12 and 24 h in the
girl and boy, respectively.
Unfortunately, atropinization does not reverse either the
central or nicotinic cholinergic signs or symptoms, parti-
cularly the muscle weakness and/or paralysis. A different
dose of pralidoxime or a continuous infusion is used in
severe poisoning up to the resolution of the symptoms or
restoration of normal plasma PCE levels [13].
This antidote is best used as early as is reasonable
before irreversible inhibition of acetylcholinesterase
occurs. A loading dose of 25 to 50 mg/kg followed by a
repetitive administration or a continuous infusion of 10
to 20 mg/kg per hour is administered until muscle
weakness and fasciculation resolve [14].
Note that health care personnel can develop OI
through either dermal or respiratory exposure, and mea-
sures should be taken in order to avoid this. In our
cases the health care personnel involved developed
headaches, but this situation was quite easily resolved by
aeration of the room where the patients were treated.
Moreover, we should advise the personnel to wear
gloves, masks and glasses when decontaminating the
patient’s skin and to hermitically seal the patients’
clothes in a closed bag [1].
Conclusion
This report emphasizes that misuse of OC, even in cases
of domestic application, may be life threatening. This
can cause acute OI even through the skin.
Management of OI consists of airway management;
administration of oxygen and fluid, atropine in increas-
ing doses and pralidoxime; as well as decontamination
of the patient’s skin.
The involved health care personnel should be aware of
the potential risk of becoming intoxicated themselves
when taking care of contaminated patients.
PCE analysis is an easy indicator of OI and can be
used for treatment monitoring.
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Figure 1 Pseudocholinesterase levels of our patients during hospitalisation.
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